MoonLake Immunotherapeutics (MLTX) Stock Could Be Above Fair Value On Book Value Concerns
MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
Is MoonLake Immunotherapeutics (MLTX) Cheap On Earnings Losses And Sonelokimab Milestones?
MoonLake Immunotherapeutics Stock In Focus After Quarterly Loss Update
MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
MoonLake Q3 EPS $(0.93) Misses $(0.78) Estimate
MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds
MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions
What's Going On with MoonLake Immunotherapeutics Stock on Thursday?
MoonLake: Downgrading To Hold As FDA Priority Review Decision Remains
MoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC Says
MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $50 Price Target
MoonLake Immunotherapeutics Files Biologics License Application To FDA For Nanobody Sonelokimab To Treat Hidradenitis Suppurativa
MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $50
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
MoonLake Immunotherapeutics Reports Topline Results From Phase 3 IZAR-1 Trial Showing Sonelokimab Met All Week 16 Endpoints In Biologic‑Naïve Psoriatic Arthritis Patients
MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.